Nektar Therapeutics NKTR Return on equity

Return on equity at other companies

AmgenAMGN

91.5%-7.7pp

Regeneron PharmaceuticalsREGN

14%-1.3pp

Artiva Biotherapeutics, Inc.ARTV

-36.6%—

CTO

Citius Oncology, Inc.CTOR

-119.9%+46.7pp

Vera TherapeuticsVERA

-71.3%+296pp

Viridian Therapeutics, Inc.VRDN

-65.7%-0.1pp

FAQ

What is Nektar Therapeutics's return on equity?

Nektar Therapeutics (NKTR) reported return on equity of -53.6% in Q1 2026.

How has Nektar Therapeutics's return on equity changed year-over-year?

Nektar Therapeutics's return on equity increased by 73.2% year-over-year, from -199.8% to -53.6%.

What is the long-term trend for Nektar Therapeutics's return on equity?

Over 5 years (2020 to 2025), Nektar Therapeutics's return on equity has grown at a 43.5% compound annual growth rate (CAGR), from -35.8% to -217.9%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.